PRTA has been the subject of a number of other reports. Zacks Investment Research raised Prothena from a sell rating to a hold rating in a research note on Monday, February 19th. BidaskClub raised Prothena from a strong sell rating to a sell rating in a research note on Saturday, February 17th. ValuEngine downgraded Prothena from a sell rating to a strong sell rating in a research note on Wednesday, February 7th. Finally, Cantor Fitzgerald reissued a buy rating and issued a $65.00 price objective on shares of Prothena in a research note on Sunday, February 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. Prothena presently has an average rating of Buy and a consensus target price of $74.91.
Shares of PRTA stock opened at $38.21 on Wednesday. Prothena has a one year low of $27.19 and a one year high of $70.00.
Hedge funds have recently modified their holdings of the stock. Fieldpoint Private Securities LLC bought a new position in shares of Prothena in the 3rd quarter valued at approximately $162,000. Teacher Retirement System of Texas bought a new position in shares of Prothena in the 3rd quarter valued at approximately $206,000. First Trust Advisors LP bought a new position in shares of Prothena in the 3rd quarter valued at approximately $212,000. HBK Investments L P bought a new position in shares of Prothena in the 4th quarter valued at approximately $213,000. Finally, SG Americas Securities LLC raised its stake in shares of Prothena by 70.8% in the 3rd quarter. SG Americas Securities LLC now owns 6,942 shares of the biotechnology company’s stock valued at $450,000 after acquiring an additional 2,878 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “Oppenheimer Reiterates $70.00 Price Target for Prothena (PRTA)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3296666/oppenheimer-reiterates-70-00-price-target-for-prothena-prta.html.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.